Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant

Rhea-AI Filing Summary

McLaughlin Gerald W. reported acquisition or exercise transactions in this Form 4 filing.

Allarity Therapeutics, Inc. director Gerald W. McLaughlin received a grant of 45,000 shares of common stock in the form of restricted stock units on January 28, 2026. These RSUs vested in full on the grant date, bringing his directly held position to 70,000 shares after the award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McLaughlin Gerald W.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	45,000	$0.00	--

Holdings After Transaction: Common Stock — 70,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 45,000 shares Post-grant holdings: 70,000 shares Grant price per share: $0.0000 per share

3 metrics

RSU grant size 45,000 shares Restricted stock units granted on January 28, 2026

Post-grant holdings 70,000 shares Total common shares held directly after the award

Grant price per share $0.0000 per share Compensation-based RSU award, not an open-market purchase

Key Terms

restricted stock units, RSUs, Amended and Restated 2021 Equity Incentive Plan, Common Stock

4 terms

restricted stock units financial

"The restricted stock units, or RSUs, granted on January 28, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"The restricted stock units, or RSUs, granted on January 28, 2026"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Amended and Restated 2021 Equity Incentive Plan financial

"pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McLaughlin Gerald W.

(Last) (First) (Middle)

C/O ALLARITY THERAPEUTICS, INC.

123 E TARPON AVE

(Street)

TARPON SPRINGS FLORIDA 34689

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allarity Therapeutics, Inc. [ ALLR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		45,000(1)	A	$0	70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.

	/s/ Gerald W. McLaughlin	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Allarity Therapeutics (ALLR) report for Gerald W. McLaughlin?

Allarity Therapeutics reported that director Gerald W. McLaughlin received 45,000 restricted stock units of common stock. The grant is recorded as an award transaction, increasing his directly held position to 70,000 shares after the award.

How many Allarity Therapeutics (ALLR) shares does Gerald W. McLaughlin hold after this grant?

After the grant, Gerald W. McLaughlin holds 70,000 shares of Allarity Therapeutics common stock directly. This figure includes the 45,000 restricted stock units that were granted and fully vested on January 28, 2026, under the company’s equity incentive plan.

What type of equity award did Allarity Therapeutics (ALLR) grant to Gerald W. McLaughlin?

Gerald W. McLaughlin received restricted stock units, or RSUs, tied to Allarity Therapeutics common stock. The award covered 45,000 shares and was issued under the company’s Amended and Restated 2021 Equity Incentive Plan, a standard structure for director compensation.

When did Gerald W. McLaughlin’s Allarity Therapeutics (ALLR) RSUs vest?

The 45,000 restricted stock units granted to Gerald W. McLaughlin vested in full on January 28, 2026. Same-day vesting means he immediately obtained the underlying common shares on the grant date, rather than over a multi-year vesting schedule.

Was there a purchase price for Gerald W. McLaughlin’s Allarity Therapeutics (ALLR) RSU grant?

The filing lists a transaction price per share of $0.0000 for the 45,000-share RSU grant. This indicates the award was compensation-based rather than an open-market purchase, consistent with typical director equity grants in public companies.